Back to results5HT3 Antagonism and Auditory Gating in Schizophrenia
Primary Purpose
Schizophrenia
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ondansetron
neuropsychological testing
nicotine
haloperidol
Sponsored by
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring schizophrenia, ondansetron, nicotine, haloperidol
Eligibility Criteria
Subjects with diagnosed with schizophrenia will be studied.
Sites / Locations
- VAMC
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00018850
First Posted
July 3, 2001
Last Updated
January 20, 2009
Sponsor
US Department of Veterans Affairs
1. Study Identification
Unique Protocol Identification Number
NCT00018850
Brief Title
5HT3 Antagonism and Auditory Gating in Schizophrenia
Official Title
5HT3 Antagonism and Auditory Gating in Schizophrenia
Study Type
Interventional
2. Study Status
Record Verification Date
December 2004
Overall Recruitment Status
Completed
Study Start Date
June 1998 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
June 2003 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
US Department of Veterans Affairs
4. Oversight
5. Study Description
Brief Summary
The target groups in this study are brain waves and neurotransmitters (chemical messengers) in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will help understand more about normal brain functioning and how that functioning differs in people with schizophrenia. Another purpose of this study is to determine how the altered brain functioning in schizophrenia contributes the symptoms found in the illness.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
Keywords
schizophrenia, ondansetron, nicotine, haloperidol
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
ondansetron
Intervention Type
Behavioral
Intervention Name(s)
neuropsychological testing
Intervention Type
Drug
Intervention Name(s)
nicotine
Intervention Type
Drug
Intervention Name(s)
haloperidol
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Subjects with diagnosed with schizophrenia will be studied.
Facility Information:
Facility Name
VAMC
City
Denver
State/Province
Colorado
ZIP/Postal Code
80013
Country
United States
12. IPD Sharing Statement
Learn more about this trial
5HT3 Antagonism and Auditory Gating in Schizophrenia
We'll reach out to this number within 24 hrs